CytomX Therapeutics, a clinical-stage biopharmaceutical company focused on cancer treatments, will release its second quarter 2026 financial results on August 6, 2026, after U.S. markets close. The company will host a conference call and webcast to discuss the results. CytomX specializes in conditionally activated biologics and has a pipeline including therapies for metastatic colorectal cancer and melanoma. This update is important for investors tracking progress in innovative cancer therapies.
Uniswap has reached $71.1 billion in trading volume over the past 30 days, reinforcing its position as the top decentralized exchange (DEX). Its consistent high volumes, including $21.3 billion in the last week and nearly $2 billion in a single day, ...
Litecoin whale addresses holding $1M-$10M and above $10M have decreased to levels last seen at the 2022 market bottom, signaling reduced large-holder activity during this market phase. On-chain analyst Joao Wedson notes this contraction resembles pas...
Sui (SUI) price trades near $0.72 after a fresh TD Sequential buy signal on the 12-hour chart, which previously predicted a 17% rally and momentum shift. The price tests a critical support zone between $0.71 and $0.73, with a break below $0.71 potent...
Ripple sees a $13 trillion opportunity in the corporate treasury sector for expanding its stablecoin business, leveraging its Ripple Treasury platform acquired through GTreasury. With around 1,200 corporate clients managing cross-border and domestic ...
Bitcoin is losing its status as independent 'digital gold' and is now closely tracking the U.S. stock market, particularly the S&P 500. This growing correlation raises concerns that Bitcoin could face a sharp decline if U.S. equities correct, especia...
